Enfusion: TAM Penetration Continues To Progress Well

The best photo for all Investment overview I wrote about Enfusion (NYSE:ENFN) previously with a buy rating as I thought the business would continue to grow, with potential for acceleration given the visible catalysts available. Notably, valuation multiples should start to reflect their true worth when the business starts to generate profits. My recommendation remains buy-rated for ENFN as the growth outlook is still very bright, supported by ENFN's strong track record of execution. 4Q23 earnings ENFN report ...